Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

Researchers highlighted the crucial role of suppressing platelet‐derived growth factor‐related signaling in mediating the beneficial effects of empagliflozin on neointima formation and vascular smooth muscle cell function, which were independent of sodium-glucose cotransporter 2 and glycemic control.